Prolactin activation of the long form of its cognate receptor causes increased visceral fat and obesity in males as shown in transgenic mice expressing only this receptor subtype

Hormone and Metabolic Research

Volumn 43, Issue 13, 2011, Pages 931-937

  Le, J A ^a   Wilson, H M ^a   Shehu, A ^a   Devi, Y S ^a   Aguilar, T ^a   Gibori, G ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

adipose; AMP activated protein kinase; obesity; prolactin

Indexed keywords

GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; PROLACTIN; PROLACTIN RECEPTOR;

ADIPOCYTE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GLUCOSE TOLERANCE; HORMONAL REGULATION; INSULIN RESISTANCE; INSULIN SYNTHESIS; INTRAABDOMINAL FAT; LIPID STORAGE; LIPOLYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TRANSGENIC MOUSE;

ANIMALS; BLOOD GLUCOSE; FEMALE; HUMANS; INSULIN; INTRA-ABDOMINAL FAT; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OBESITY; PROLACTIN; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; UP-REGULATION;

MUS; MUS MUSCULUS;

EID: 83155181512     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1291182     Document Type: Article

References (47)

1. Kreitschmann-Andermahr I, Suarez P, Jennings R, Evers N, Brabant G. GH/IGF-I regulation in obesity mechanisms and practical consequences in children and adults. Horm Res Paediatr: 2010; 73 153 160
2. Brown L M, Gent L, Davis K, Clegg D J. Metabolic impact of sex hormones on obesity. Brain Res: 2010; 1350 77 85
3. Gade W, Schmit J, Collins M, Gade J. Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome. Clin Lab Sci: 2010; 23 51 61 quiz 6265
4. Ling C, Hellgren G, Gebre-Medhin M, Dillner K, Wennbo H, Carlsson B, Billig H. Prolactin (PRL) receptor gene expression in mouse adipose tissue: increases during lactation and in PRL-transgenic mice. Endocrinology: 2000; 141 3564 3572
5. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab: 2007; 9 464 476 (Pubitemid 47018509)
6. Hugo E R, Borcherding D C, Gersin K S, Loftus J, Ben-Jonathan N. Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes. J Clin Endocrinol Metab: 2008; 93 4006 4012
7. Brandebourg T D, Bown J L, Ben-Jonathan N. Prolactin upregulates its receptors and inhibits lipolysis and leptin release in male rat adipose tissue. Biochem Biophys Res Commun: 2007; 357 408 413 (Pubitemid 46603146)
8. Fleenor D, Arumugam R, Freemark M. Growth hormone and prolactin receptors in adipogenesis: STAT-5 activation, suppressors of cytokine signaling, and regulation of insulin-like growth factor I. Horm Res: 2006; 66 101 110 (Pubitemid 44213993)
9. LaPensee C R, Horseman N D, Tso P, Brandebourg T D, Hugo E R, Ben-Jonathan N. The prolactin-deficient mouse has an unaltered metabolic phenotype. Endocrinology: 2006; 147 4638 4645 (Pubitemid 44402169)
10. Nilsson L A, Roepstorff C, Kiens B, Billig H, Ling C. Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Horm Metab Res: 2009; 41 747 751
11. Freemark M, Fleenor D, Driscoll P, Binart N, Kelly P. Body weight and fat deposition in prolactin receptor-deficient mice. Endocrinology: 2001; 142 532 537 (Pubitemid 32222400)
12. Fleenor D, Oden J, Kelly P A, Mohan S, Alliouachene S, Pende M, Wentz S, Kerr J, Freemark M. Roles of the lactogens and somatogens in perinatal and postnatal metabolism and growth: studies of a novel mouse model combining lactogen resistance and growth hormone deficiency. Endocrinology: 2005; 146 103 112 (Pubitemid 40051729)
13. Ling C, Billig H. PRL receptor-mediated effects in female mouse adipocytes: PRL induces suppressors of cytokine signaling expression and suppresses insulin-induced leptin production in adipocytes in vitro. Endocrinology: 2001; 142 4880 4890 (Pubitemid 33022364)
14. Ling C, Svensson L, Oden B, Weijdegard B, Eden B, Eden S, Billig H. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab: 2003; 88 1804 1808 (Pubitemid 36623408)
15. Nilsson L, Binart N, Bohlooly Y M, Bramnert M, Egecioglu E, Kindblom J, Kelly P A, Kopchick J J, Ormandy C J, Ling C, Billig H. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun: 2005; 331 1120 1126 (Pubitemid 40692475)
16. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf): 1998; 48 547 553 (Pubitemid 28252990)
17. Schmid C, Goede D L, Hauser R S, Brandle M. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly: 2006; 136 254 258
18. Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary: 2009; 12 96 104
19. Naliato E C, Violante A H, Gaccione M, Caldas D, Lamounier Filho A, Loureiro C R, Fontes R, Schrank Y, Costa F S, Colao A. Body fat in men with prolactinoma. J Endocrinol Invest: 2008; 31 985 990
20. Devi Y S, Shehu A, Stocco C, Halperin J, Le J, Seibold A M, Lahav M, Binart N, Gibori G. Regulation of transcription factors and repression of Sp1 by prolactin signaling through the short isoform of its cognate receptor. Endocrinology: 2009; 150 3327 3335
21. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J: 1994; 13 4361 4369 (Pubitemid 24295208)
22. Le J. Prolactin Signaling Through the Long Form of its Receptor and its Role in Ovarian and Adipocyte Function. Chicago, USA University of Illinois at Chicago: 2010; Thesis
23. Horseman N D, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle S J, Smith F, Markoff E, Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J: 1997; 16 6926 6935 (Pubitemid 27520793)
24. Halperin J, Devi S Y, Elizur S, Stocco C, Shehu A, Rebourcet D, Unterman T G, Leslie N D, Le J, Binart N, Gibori G. Prolactin signaling through the short form of its receptor represses forkhead transcription factor FOXO3 and its target gene galt causing a severe ovarian defect. Mol Endocrinol: 2008; 22 513 522 (Pubitemid 351185946)
25. Shehu A, Mao J, Gibori G B, Halperin J, Le J, Devi Y S, Merrill B, Kiyokawa H, Gibori G. Prolactin receptor-associated protein/17beta- hydroxysteroid dehydrogenase type 7 gene (Hsd17b7) plays a crucial role in embryonic development and fetal survival. Mol Endocrinol: 2008; 22 2268 2277
26. Ormandy C J, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev: 1997; 11 167 178 (Pubitemid 27081894)
27. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky J M, Evans R M. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA.: 2003; 100 15712 15717 (Pubitemid 38021055)
28. Hevener A L, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans R M, Olefsky J. Muscle-specific Pparg deletion causes insulin resistance. Nat Med: 2003; 9 1491 1497 (Pubitemid 38004776)
29. Liu P Y, Handelsman D J. The present and future state of hormonal treatment for male infertility. Hum Reprod Update: 2003; 9 9 23 (Pubitemid 36305580)
30. Aleem M, Choudhari J, Padwal V, Balasinor N, Parte P, Gill-Sharma M K. Hyperprolactinemia affects spermiogenesis in adult male rats. J Endocrinol Invest: 2005; 28 39 48 (Pubitemid 43162808)
31. Gill-Sharma M K. Prolactin and male fertility: the long and short feedback regulation. Int J Endocrinol: 2009; 2009 687259
32. Henderson D C, Doraiswamy P M. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry: 2008; 69 01 32 44
33. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets: 2004; 5 279 299 (Pubitemid 38372313)
34. Scislowski P W, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, Cincotta A H. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord: 1999; 23 425 431 (Pubitemid 29182403)
35. Zhang Y, Scislowski P W, Prevelige R, Phaneuf S, Cincotta A H. Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. Metabolism: 1999; 48 1033 1040 (Pubitemid 29374923)
36. Cincotta A H, Meier A H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care: 1996; 19 667 670 (Pubitemid 26182986)
37. Haluzik M, Colombo C, Gavrilova O, Chua S, Wolf N, Chen M, Stannard B, Dietz K R, Le Roith D, Reitman M L. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology: 2004; 145 3258 3264 (Pubitemid 38829998)
38. Andrikopoulos S, Massa C M, Aston-Mourney K, Funkat A, Fam B C, Hull R L, Kahn S E, Proietto J. Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. J Endocrinol: 2005; 187 45 53 (Pubitemid 41556400)
39. Almind K, Kahn C R. Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. Diabetes: 2004; 53 3274 3285 (Pubitemid 39571714)
40. Shepherd P R, Kahn B B. Glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus. N Engl J Med: 1999; 341 248 257 (Pubitemid 29334524)
41. Graham T E, Kahn B B. Tissue-specific alterations of glucose transport and molecular mechanisms of intertissue communication in obesity and type 2 diabetes. Horm Metab Res: 2007; 39 717 721 (Pubitemid 350099818)
42. Guo K Y, Halo P, Leibel R L, Zhang Y. Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. Am J Physiol Regul Integr Comp Physiol: 2004; 287 R112 R119 (Pubitemid 38856317)
43. Ruderman N B, Saha A K, Kraegen E W. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology: 2003; 144 5166 5171 (Pubitemid 37476042)
44. Linher-Melville K, Zantinge S, Sanli T, Gerstein H, Tsakiridis T, Singh G. Establishing a relationship between prolactin and altered fatty acid beta-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer: 2011; 11 56
45. Clevenger C V, Chang W P, Ngo W, Pasha T L, Montone K T, Tomaszewski J E. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Pathol: 1995; 146 695 705
46. Qazi A M, Tsai-Morris C H, Dufau M L. Ligand-Independent Homo- and Hetero-Dimerization of Human Prolactin Receptor Variants: Inhibitory Action of the Short Forms by Heterodimerization. Mol Endocrinol: 2006; 20 1912 1923 (Pubitemid 44148093)
47. Gadd S L, Clevenger C V. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol: 2006; 20 2734 2746 (Pubitemid 44833532)